Cytoreductive surgery for recurrent ovarian cancer: A meta-analysis

Gynecologic Oncology

Volumn 112, Issue 1, 2009, Pages 265-274

  Bristow, Robert E ^a   Puri, Isha ^a   Chi, Dennis S ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cytoreductive surgery; Ovarian cancer; Recurrence

Indexed keywords

ALTRETAMINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; MELPHALAN; MITOMYCIN C; PACLITAXEL; PLATINUM; TOPOTECAN; VINCRISTINE; VINDESINE;

AGE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; DISEASE FREE INTERVAL; HISTOLOGY; HUMAN; INTESTINE RESECTION; MEDLINE; MULTIPLE LINEAR REGRESSION ANALYSIS; OVARY CANCER; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SURVIVAL TIME;

FEMALE; GYNECOLOGIC SURGICAL PROCEDURES; HUMANS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS;

EID: 57649083923     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2008.08.033     Document Type: Review

References (66)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., et al. Cancer statistics 2008. CA Cancer J Clin 58 (2008) 71-96
2. Meigs J.V. Tumors of the female pelvic organs (1934), MacMillan, New York
3. Griffiths C.T. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma. Natl Cancer Inst Monogr 42 (1975) 101-104
4. Hoskins W.J., Bundy B.N., Thigpen J.T., and Omura G.A. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol 47 (1992) 159-166
5. Hoskins W.J., McGuire W.P., Brady M.F., Homesley H.D., Creasman W.T., Berman M., et al. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol 170 (1994) 974-979
6. Chi D.S., Liao J.B., Leon L.F., Venkatraman E.S., Hensley M.L., Bhaskaran D., et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma. Gynecol Oncol 82 (2001) 532-537
7. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., and Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20 (2002) 1248-1259
8. Berek J.S., Hacker N.F., Lagasse L.D., Nieberg R.K., and Elashoff R.M. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol 61 (1983) 189-193
9. Bristow R.E., Lagasse L.D., and Karlan B.Y. Secondary surgical cytoreduction for advanced epithelial ovarian cancer: patient selection and review of the literature. Cancer 78 (1996) 2049-2062
10. Rubin D.B. Inference and missing data. Biometrika 63 (1976) 581-592
11. Schafer J.L. Analysis of incomplete multivariate data (1997), Chapman and Hall/CRC, London
12. Morris M., Gershenson D.M., Wharton J.T., Copeland L.J., Edwards C.L., and Stringer C.A. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 34 (1989) 334-338
13. Jänicke F., Hölscher M., Kuhn W., von Hugo R., Pache L., Siewart J.R., et al. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 70 (1992) 2129-2136
14. Segna R.A., Dottino P.R., Mandell J.P., Konsker K., and Cohen C.J. Secondary cytoreduction for ovarian cancer following cisplatin therapy. J Clin Oncol 11 (1993) 434-439
15. Eisenkop S.M., Friedman R.L., and Wang H.J. Secondary cytoreductive surgery for recurrent ovarian cancer. A prospective study. Cancer 76 (1995) 1606-1614
16. Vaccarello L., Rubin S.C., Vlamis V., Wong G., Jones W.B., Lewis J.L., et al. Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol Oncol 57 (1995) 61-65
17. Lichtenegger W., Sehouli J., Buchmann E., Karajanev C., and Weidmann H. Operative results after primary and secondary debulking-operations in advanced ovarian cancer (AOC). J Obstet Gynaecol Res 24 (1998) 447-451
18. Landoni F., Pellgrino A., Cormio G., Milani R., Maggioni A., and Mangioni C. Platin-based chemotherapy and salvage surgery in recurrent ovarian cancer following negative second-look laparotomy. Acta Obstet Gynecol Scand 77 (1998) 233-237
19. Cormio G., di Vagno G., Cazzolla A., Bettocchi S., di Gesu G., Loverro G., et al. Surgical treatment of recurrent ovarian cancer: report of 21 cases and review of the literature. Eur J Obstet Gynecol Reprod Biol 86 (1999) 185-188
20. Gadducci A., Iacconi P., Cosio S., Fanucchi A., Cristofani R., and Genazzani R. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer. Gynecol Oncol 79 (2000) 344-349
21. Zang R.Y., Zhang Z.Y., Li Z.T., Chen J., Tang M.Q., Liu Q., et al. Effect of cytoreductive surgery on survival of patients with recurrent epithelial ovarian cancer. J Surg Oncol 75 (2000) 24-30
22. Chen L.M., Leuchter R.S., Lagasse L.D., and Karlan B.Y. Splenectomy and surgical cytoreduction for ovarian cancer. Gynecol Oncol 77 (2000) 362-368
23. Eisenkop S.M., Friedman R.L., and Spirtos N.M. The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian cancer. Cancer 88 (2000) 144-153
24. Tay E.H., Grant P.T., Gebski V., and Hacker N.F. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Obstet Gyenecol 99 (2002) 1008-1013
25. Bristow R.E., Gossett D.R., Shook D.R., Zahurak M.L., Tomacruz R.S., Armstrong D.K., et al. Recurrent micropapillary serous carcinoma. The role of secondary cytoreductive surgery. Cancer 95 (2002) 791-800
26. Yoon S.S., Jarnagin W.R., Fong Y., DeMatteo R.P., Barakat R.R., Blumgart L.H., et al. Resection of recurrent ovarian or fallopian tube carcinoma involving the liver. Gynecol Oncol (2003) 383-388
27. Zang R.Y., Li Z.T., Zhang Z.Y., and Cai S.M. Surgery and salvage chemotherapy for Chinese women with recurrent advanced epithelial ovarian carcinoma: a retrospective case-control study. Int J Gynecol Cancer 13 (2003) 419-427
28. Merideth M.A., Cliby W.A., Keeney G.L., Lesnick T.G., Nagorney D.M., and Podratz K.C. Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol Oncol 89 (2003) 16-21
29. Look M., Chang D., and Sugarbaker P.H. Long-term results of cytoreductive surgery for advanced and recurrent epithelial ovarian cancers and papillary serous carcinoma of the peritoneum. Int J Gynecol Cancer 13 (2003) 764-770
30. Loizzi V., Chan J.K., Osann K., Cappuccini F., DiSaia P.J., and Berman M.L. Survival outcomes in patients with recurrent ovarian cancer who were treated with chemoresistance assay-guided chemotherapy. Am J Obstet Gynecol 189 (2003) 1301-1307
31. Leitao M.M., Kardos S., Barakat R.R., and Chi D.S. Tertiary cytoreduction in patients with recurrent ovarian carcinoma. Gynecol Oncol 95 (2004) 181-188
32. Zang R.Y., Li Z.T., Tang J., Cheng X., Cai S.M., Zhang Z.Y., et al. Secondary cytoreductive surgery for patients with relapsed ovarian carcinoma: who benefits?. Cancer 100 (2004) 1152-1161
33. Zanon C., Clara R., Chiappino I., Bortolini M., Cornaglia S., Simone P., et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg 28 (2004) 1040-1045
34. Uzan C., Morice P., Rey A., Pautier P., Camatte S., Lhommé C., et al. Outcomes after combined therapy including surgical resection in patients with epithelial ovarian cancer recurrence(s) exclusively in lymph nodes. Ann Surg Oncol 11 (2004) 658-664
35. Gronlund B., Lundvall L., Christensen I.J., Knudsen J.B., and Hogdall C. Surgical cytoreduction in recurrent ovarian carcinoma in patients with complete response to paclitaxel-platinum. Eur J Surg Oncol 31 (2005) 67-73
36. Güngör M., Ortac F., Arvas M., Kösebay D., Sönmezer M., and Köse K. The role of secondary cytoreductive surgery for recurrent ovarian cancer. Gynecol Oncol 97 (2005) 74-79
37. Yap O.W.S., Kapp D.S., Teng N.N.H., and Husain A. Intraoperative radiation therapy in recurrent ovarian cancer. Int J Radiation Oncology Biol Phys 63 (2005) 1114-1121
38. Onda T., Yoshikawa H., Yasugi T., Yamada M., Matsumoto K., and Taketani Y. Secondary cytoreductive surgery for recurrent epithelial ovarian carcinoma: proposal for patient selection. Br J Cancer 92 (2005) 1026-1032
39. Ayhan A., Gultekin M., Taskiran C., Aksan G., Celik N.Y., Dursun P., et al. The role of secondary cytoreduction in the treatment of ovarian cancer: Hacettepe University experience. Am J Obstet Gynecol 194 (2006) 49-56
40. Matsumoto A., Higuchi T., Yura S., Mandai M., Kariya M., Takakura K., et al. Role of salvage cytoreductive surgery in the treatment of patients with recurrent ovarian cancer after platinum-based chemotherapy. J Obstet Gynecol Res 37 (2006) 580-587
41. Manci N., Bellati F., Muzii L., Calcagno M., Alon S.A., Pernice M., et al. Splenectomy during secondary cytoreduction for ovarian cancer disease recurrence: surgical and survival data. Ann Surg Oncol 13 (2006) 1717-1723
42. Chi D.S., McCaughty K., Diaz J.P., Huh J., Schwabenbauer S., Hummer A.J., et al. Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma. Cancer 106 (2006) 1933-1939
43. Harter P., du Bois A., Hahmann M., et al. Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial. Ann Surg Oncol 13 (2006) 1702-1710
44. Rufian S., Munoz-Casares F., Briceno J., Diaz C.J., Rubio M.J., Ortega R., et al. Radical surgery-peritonectomy and intraoperative chemotherapy for treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol 94 (2006) 316-324
45. Helm C.W., Randall-Whitis L., Martin II R.S., Metzinger D.S., Gordinier M.E., Parker L.P., et al. Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma. Gynecol Oncol 105 (2007) 90-96
46. Salani R., Santillan A., Zahurak M.L., Giuntoli II R.L., Gardner G.J., Armstrong D.K., et al. Secondary cytoreductive surgery for localized, recurrent epithelial ovarian cancer: analysis of prognostic factors and survival outcome. Cancer 109 (2007) 685-691
47. Santillan A., Karam A.K., Li A.J., Giuntoli R., Gardner G.J., Cass I., et al. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer. Gynecol Oncol 104 (2007) 686-690
48. Benedetti Panici P., De Vico A., Bellati F., Manci N., Perniola G., Basile S., et al. Secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer. Ann Surg Oncol 14 (2007) 1136-1142
49. Benedetti Panici P., Perniola P., Angioli R., Zullo M.A., Manci N., Palaia I., et al. Bulky lymph node resection in patients with recurrent epithelial ovarian cancer: impact of surgery. Int J Gynecol Cancer 17 (2007) 1245-1251
50. Cotte E., Glehen O., Mohamed F., Lamy F., Falandry C., Gofier F., et al. Cytoreductive surgery and intraperitoneal chemohyperthermia for chemoresistant and recurrent advanced epithelial ovarian cancer: prospective study of 81 patients. World J Surg 31 (2007) 1813-1820
51. Ozols R.F., Bundy B.N., Greer B.E., Fowler J.M., Clarke-Pearson D., Burger R.A., et al., Gynecologic Oncology Group. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21 (2003) 3194-3200
52. Ozols R.F., Rubin S.C., Thomas G.M., and Robboy S.J. Epithelial ovarian cancer. In: Hoskins W.J., Perez C.A., Young R.C., Barakat R., Markman M., and Randall M. (Eds). Principles and practice of gynecologic oncology. 4th ed (2005), Lippincott-Raven Publishers, Philadelphia, PA 895-987
53. Munkarah A.R., and Coleman R.L. Critical evaluation of secondary cytoreduction in recurrent ovarian cancer. Gynecol Oncol 95 (2004) 273-280
54. Bristow R.E., and Chi D.S. Platinum-based neoadjuvant chemotherapy and interval surgical cytoreduction for advanced ovarian cancer: a meta-analysis. Gynecol Oncol 103 (2006) 1070-1076
55. Balvert-Locht H.R., Coeberg J.W., Hop W.C., Brölmann H.A., Crommelin M., van Wijck D.J., et al. Improved prognosis of ovarian cancer in the Netherlands during the period 1975-1985: a registry-based study. Gynecol Oncol 42 (1991) 3-8
56. Bjorge T., Engeland A., Sundfor K., and Tropé C.G. Prognosis of 2,800 patients with epithelial ovarian cancer diagnosed during 1975-1994 and treated at the Norwegian Radium Hospital. Acta Obstet Gynecol Scand 77 (1998) 777-781
57. Eisenkop S.M., Friedman R.L., and Wang H.J. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 69 (1998) 103-108
58. Aletti G.D., Dowdy S.C., Gostout B.S., Jones M.B., Stanhope C.R., Wilson T.O., et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 107 (2006) 77-85
59. Hunter R.W., Alexander N.D.E., and Soutter W.P. Meta-analysis of surgery in advanced ovarian carcinoma: is maximum cytoreductive surgery an independent determinant of prognosis?. Am J Obstet Gynecol 166 (1992) 504-511
60. Ben-David Y., Rosen B., Franssen E., Einarson T., and Szyfer I. Meta-analysis comparing cisplatin total dose intensity and survival. Gynecol Oncol 59 (1995) 93-101
61. Voest E.E., van Houwelingen J.C., and Neijt J.P. A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log [relative risk]) as main objective. Eur J Cancer Clin Oncol 25 (1989) 711-720
62. The ICON and AGO Collaborators. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 361 (2003) 2099-2106
63. Cantù M.G., Buda A., Parma G., Rossi R., FLoriani I., Bonazzi C., et al. Randomized controlled trial of single-agent paclitaxel versus cyclophosphamide, doxorubicin, and cisplatin in patients with recurrent ovarian cancer who responded to first-line platinum-based regimens. J Clin Oncol 20 (2002) 1232-1237
64. Bolis G., Scarfone G., Giardina G., Villa A., Mangili G., Melpignano M., et al. Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer 81 (2001) 3-9
65. Pfisterer J., Plant M., Vergote I., du Bois A., Hirte H., Lacave A.J., et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24 (2006) 4699-4707
66. Gordon A.N., Tonda M., Sun S., Rackoff W., and Doxil Study 30-49 Investigators. Long-term survival advantage for women treated with pegylated doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer. Gynecol Oncol 95 (2004) 1-8